Biolink Secures Hundreds of Millions RMB New Financing to Fuel Innovations in Bioprocessing “Made in China”

Today, Biolink is pleased to announce the successful completion of a new multi-hundred million RMB strategic financing round. This round was led by Cathay Capital and included participation from distinguished investment firms including ALWIN Capital, Haihe Asymchem Industrial Fund, Shenzhen Capital Group, Haiwang Capital, and Zoo Capital. This financing will provide crucial support for Biolink’s business development and product R&D, accelerating its domestic and global footprint and driving continuous advancements in bioprocessing technology.

Since its foundation, Biolink has been committed to tackling critical challenges in bioprocessing, specializing in the development of efficient, safe, and competitive solutions for biological products such as vaccines, antibody drugs, recombinant protein drugs, cell therapy and gene therapy. Biolink’s product portfolio cover core equipment and consumables for cell culture, one-time stock solutions, chromatography, tertiary filtration, and hydration processes, complemented by end-to-end process development and validation services.

As an innovation-driven company, Biolink prioritizes R&D investment, establishing dedicated research platforms and specialized teams across its product lines to continuously introduce self-innovated products for key processing stages. This strategy has significantly enhanced the competitiveness and technical sophistication of Biolink’s offerings. The company currently holds about 200 technology patents and has obtained ISO 9001, ISO 13485, CNAS, and CMA certifications, ensuring its products meet stringent global quality and compliance standards.

In 2024, Biolink has actively participated in major industry events both domestically and internationally. The company has also collaborated with industry partners to establish the “Antibody Drug Specialty Institute” and has launched the bioprocessing roadshows, offering insights into critical technologies. Through these customer events, Biolink engages directly with clients, addressing their pressing needs to improve efficiency and reduce costs. The company also shares market insights and key technical expertise in collaboration with industry experts, fostering invaluable exchanges that have been met with enthusiastic reception from clients.

These achievements in innovation and proactive market engagement have positioned Biolink as a leading, reliable provider in the biopharmaceutical industry, gaining the recognition of numerous biopharmaceutical companies worldwide.

Chen Zhi, Founder and Chairman of Biolink, remarked, “We are grateful for the support and trust of our investors. Biolink remains focused on breakthrough technologies, enriching and upgrading our product lines, and advancing biopharmaceutical solutions that are both efficient and cost-effective. We are confident in our partnership with our investors and in Biolink’s role in driving forward China’s biopharmaceutical sector with robust momentum.”

This financing marks a new milestone in Biolink’s growing influence within the bioprocessing sector. As capital and technology continue to propel Biolink forward, the company is poised to make even greater strides in overcoming bioprocessing challenges, offering forward-thinking innovations and high-quality products that will help the industry reach new heights.

Popular Bioprocessing Products

Puredex<sup>®</sup> Resins for Ion Exchange Chromatography

Puredex^® Resins for Ion Exchange Chromatography

CytoLinX<sup>®</sup> WB Single-use Cell Culture Bag

CytoLinX^® WB Single-use Cell Culture Bag

Puredex^® Cyto-1 Microcarrier

Link With Us Now!

Want to know more about BioLink bioprocessing products? Feel free to contact BioLink now!

Email

info@biolink.com

Phone

+86-400-058-9000

ADDRESS

News & Events

Process Characteristics Related to Microcarriers

15 Oct 2024